0001493152-21-029417 Sample Contracts

Contract
Convertible Loan Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
SERVICE AGREEMENT
Service Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

This Service Agreement (“Agreement”) is made of and entered into on 08th September 2021 between CytoMed Therapeutics (Malaysia) Sdn. Bhd. (“Company”) and Choo Chee Kong (“Service Provider”).

Sample 1Sample 2Sample 3
Contract
Put Option Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3
Contract
Licence Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3
Contract
Shareholders Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3
Contract
Licence Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3
Contract
Licence Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Sample 1Sample 2Sample 3
dated ___________ (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscription agreement Relating to shares in the capital of CYTOMED THERAPEUTICS PTE LTD
Subscription Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Sample 1
ADDENDUM TO LICENCE AGREEMENT
Licence Agreement • November 19th, 2021 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations

ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as “A*ccelerate”) ; and

Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.